Pre-market hot trades in US stocks: Greenlane pre-market down 10.76%; Lakewood-Amedex Biotherapeutics pre-market up 5.46%

Pre-market Hot Trades in US Stocks Greenlane is down 10.76% in pre-market trading. Based on recent key news: On April 27, Greenlane regained compliance with Nasdaq's minimum bid price rule, avoiding delisting risk. Nasdaq confirmed that Greenlane meets all continued listing standards, which had a positive impact on the stock price but failed to prevent the pre-market decline. On April 27, Greenlane announced that it is the only Nasdaq-listed company focusing on Berachain's liquidity proof infrastructure, providing traditional market access to returns on digital assets. Although this strategic positioning may attract investors, the market reaction remains negative. On April 21, Nasdaq notified the company that it had regained compliance with the minimum bid requirements, canceling the scheduled hearing, and the stock continues to trade on the Nasdaq Capital Market. Although this news alleviated delisting concerns, it failed to boost the stock price. The digital asset market is highly volatile and requires caution. Lakewood-Amedex Biotherapeutics is up 5.46% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Top Gainers in Pre-market US Stocks Direct Digital is up 45.31% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Calidi Biotherapeutics is up 35.71% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Profusa is up 26.49% in pre-market trading. Based on recent key news: On April 24, Profusa Inc. released the latest announcement through the EDGAR system of the U.S. Securities and Exchange Commission, announcing that its new product has received FDA approval. This news significantly raised market expectations for the company's future growth, driving the stock price sharply higher. On April 23, Profusa Inc. signed a strategic cooperation agreement with a large medical device company to jointly develop new biosensor technology. This move is seen by the market as an important step for the company to expand its business scope, further boosting investor confidence. On April 22, analysts generally raised their earnings forecasts for Profusa Inc., expecting significant revenue growth from its new products. The optimistic earnings outlook attracted a large amount of buying, driving the stock price up. The medical device industry has performed strongly recently, with significant capital inflows